Q3 FY2026 · ended Sep 30, 2026 · Revenue $234,000, +23.2% YoY · Filed Oct 27, 2026
Nautilus Biotechnology, Inc. (NAUT) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $234,000 and a net loss of $15.6 million. Free cash flow was -$14.7 million. As of Sep 30, 2026 it held $114.3 million in cash and investments and $26.7 million in total debt.
Revenue
$234,000
+23.2% vs prior quarter
Net income
$-15.64M
-15.2% vs year-ago quarter
Operating cash flow
$-13.28M
-20.4% vs year-ago quarter
Free cash flow
$-14.73M
-28.6% vs year-ago quarter
EPS
$-0.12
-9.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
127.37M
+0.8% vs year-ago quarter
Net cash
$87.60M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- NAUT (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808805
- Former names
- ARYA Sciences Acquisition Corp III (until Jun 8, 2021)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $234,000 | $190,000 | — | — | — |
| Net income | -$15.6M | -$14.5M | -$14.7M | -$13.8M | -$13.6M |
| Diluted EPS | -$0.12 | -$0.11 | -$0.12 | -$0.11 | -$0.11 |
| Operating cash flow | -$13.3M | -$13.7M | -$13.1M | -$12.4M | -$11.0M |
| Free cash flow | -$14.7M | -$14.2M | -$13.6M | -$12.6M | -$11.5M |
| Total assets | $148.9M | $163.6M | $177.8M | $191.1M | $200.9M |
| Total liabilities | $32.4M | $32.5M | $33.4M | $34.1M | $31.8M |
| Stockholders' equity | $116.6M | $131.1M | $144.4M | $157.0M | $169.1M |
| Cash and investments | $114.3M | $129.2M | $143.4M | $156.1M | $168.5M |
| Total debt | $26.7M | $27.8M | $28.9M | $30.0M | $27.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 11, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 328 Nautilus Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.